- Angel Group's first industrialized strain of probiotics anchors strategic transformation towards biotechnology
YICHANG, China, Sept. 20, 2023 /PRNewswire/ -- Angel Group ("Angel") is a leading company in the field of biotechnology, driving progress and innovation in sectors such as bioagriculture and biohealth. Recently, Angel successfully achieved large-scale production of the Dangxiong LB VIII probiotic strain, a significant breakthrough that marks a milestone in Angel's strategic transformation from yeast to biotechnology.
The DB-8 comes from Dangxiong, which is located at an altitude of 4,500 meters, where there are towering snow-capped mountains and wide grasslands. This edible probiotic strain belongs to Lactobacillus delbrueckii subsp. Lactis and essentially Angel have introduced their first self-developed yogurt starter culture, Yo-Fru1.
Angel R&D team regularly visited Tibet and collected more than 100 precious plateau probiotic samples from more than 20 counties and townships of five cities and one district, and continuously expands its Qinghai Tibet Plateau Probiotic Bank, which is the main driving force to address the plateau probiotic development bottleneck.
Collecting probiotic strains is only the first step: isolation, identification, safety evaluation and selection of the best strains is a complex task. Consequently, Angel expanded the R&D team and acquired advanced equipment to find the best probiotic strain and develop Yo-Fru1.
DB-8 has the advantages of producing natural fruit acid and aroma in its metabolites, making it perfect for Angel to develop differentiated yogurt products.
In the process of industrializing DB-8 in product application, Angel repeatedly experimented to improve the taste, texture, formula cleanliness and more, sought professional advice and acquired precise guidance in terms of raw material ratio, optimization process and online test production.
Angel's corporate spirit of "pursuing excellence, innovation and continuing to improve" has relentlessly driven the company to establish integrated biotechnology design in the fields of food and health, biomedicine, bioagriculture and biomaterials.
"Angel is evolving from a leader in yeast production to becoming an innovative global biotechnology company; the strategic transformation not only brings challenges but also enormous opportunities," said Xiong Tao, president of Angel group. "With a vision of 'Develop Biotechnology, Innovate for Healthy Living', Angel aspires to become the world's leading biotechnology company."
Angel is also taking advantage of privileged resources to promote international development, and has invested and built factories around the world, and established subsidiaries in the US, Germany, Singapore and Mexico to achieve localization and expand its presence in the markets. foreign.
Photo - https://mma.prnewswire.com/media/2214789...
Logo - https://mma.prnewswire.com/media/1586948...
View original content: https://www.prnewswire.com/news-releases/primera-cepa-industrializada-de-probioticos-de-angel-group-301932685.html